NC
INDP icon

Nexthera Capital’s Indaptus Therapeutics INDP Stock Holding History

Nexthera Capital’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-123
Closed -$2.47M – 43
2017
Q3 		$2.47M Buy
+123
New +$1.77M 0.64% 31
2017
Q1 		– Sell
-62
Closed -$791K – 42
2016
Q4 		$791K Buy
+62
New +$724K 0.46% 34

Other funds holding INDP

ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Nexthera Capital's INDP Position: Q4 2017 in Review

Nexthera Capital sold out of Indaptus Therapeutics (INDP) in Q4 2017, closing a stake of 123 shares — an estimated $2.47M sold.

Nexthera Capital first reported a position in INDP in Q4 2016 and held it in 2 quarters. The position peaked at $2.47M in Q3 2017. 20 funds tracked by Wall St. Rank hold INDP as of Q4 2017.

  • Nexthera Capital reported no remaining Indaptus Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nexthera Capital sold 123 Indaptus Therapeutics shares in Q4 2017, an estimated $2.47M.
  • Nexthera Capital first reported a position in Indaptus Therapeutics in Q4 2016 and held it in 2 quarters.
  • Nexthera Capital's Indaptus Therapeutics position peaked at $2.47M in Q3 2017.
  • 20 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2017.

Based on Nexthera Capital's 13F filing for Q4 2017, filed 14 Feb 2018.